![Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - ScienceDirect Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419311615-gr2.jpg)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - ScienceDirect
Vithas Hospitales on X: "La URHA de Vithas #Granada dirigida por el doctor Salomón Menjón Beltrán brinda asistencia personalizada en técnicas de inseminación artificial y #fecundación in vitro con la seguridad de
![Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY | Breast Cancer Research and Treatment Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY | Breast Cancer Research and Treatment](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10549-023-07165-x/MediaObjects/10549_2023_7165_Fig2_HTML.png)
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY | Breast Cancer Research and Treatment
![Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY | Breast Cancer Research and Treatment Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY | Breast Cancer Research and Treatment](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10549-023-07165-x/MediaObjects/10549_2023_7165_Fig1_HTML.png)